Hematopoiesis News Volume 6.08 | Mar 3 2015

Cocaine Exposure Impairs Multilineage Hematopoiesis of Human Hematopoietic Progenitor Cells Mediated by the Sigma-1 Receptor
The authors present a novel and concise investigation into the mechanism that underlies cocaine associated hematopoietic pathology. They show that cocaine impairs multilineage hematopoiesis from human progenitors from multiple donors and tissue types. [Sci Rep] Full Article

Characterization of Putative Hematopoietic Cells from Bovine Yolk Sac
Investigators identified and characterized the putative hematopoietic cells from the yolk sac of bovine embryos at different stages of gestation. The yolk sac regresses according to gestational age and embryos are characterized into groups (I-V) according to the crown-rump measurement. [J Tissue Eng Regen Med] Abstract

Cryopreservation of Cord Blood CD34⁺ Cells before or after Thrombopoietin Expansion Differentially Affects Early Platelet Recovery in NOD SCID Mice
Researchers evaluated whether the order of cryopreservation and thrombopoietin expansion affected the expansion rate and numbers of clonogenic hematopoietic progenitor cells in vitro or platelet and longer-term hematopoietic repopulation in NOD SCID mice in vivo. [Transfusion] Abstract

DNMT3A R882 Mutation Is Associated with Elevated Expression of MAFB and M4/M5 Immunophenotype of Acute Myeloid Leukemia Blasts
Scientists investigated the connection between the typical immunophenotype of leukemic blasts and mutation of DNMT3A Arg882 (R882). They discovered the relation between DNMT3A R882 mutation and the expression of monocytic differentiation genes and its clinical significance. [Leuk Lymphoma] Abstract

CLINICAL RESEARCH

Randomized Phase II Study of GMI-1070 in SCD: Reduction in Time to Resolution of Vaso-Occlusive Events and Decreased Opioid Use
Researchers studied GMI-1070 in a prospective multicenter, randomized, placebo-controlled, double-blind, Phase II study of 76 sickle cell disease patients with vaso-occlusive events. [Blood] Abstract | Press Release

Plerixafor on Demand in Ten Healthy Family Donors as a Rescue Strategy to Achieve an Adequate Graft for Stem Cell Transplantation
Researchers report ten healthy hematopoietic stem cell donors treated with plerixafor because of insufficient response to granulocyte-colony-stimulating (G-CSF) alone or contraindication to G-CSF. [Transfusion] Abstract

Long-Term Outcomes of Autologous Hematopoietic Stem Cell Transplantation with Reduced-Intensity Conditioning in Multiple Sclerosis: Physician’s and Patient’s Perspectives
Investigators present the long-term outcomes of a prospective single-center study with the analysis of the safety and efficacy of high-dose immunosuppressive therapy + autologous hematopoietic stem cell transplantation with reduced-intensity BEAM-like conditioning regimen in 99 multiple sclerosis patients. [Ann Hematol] Abstract

One Million Hemopoietic Stem-Cell Transplants: A Retrospective Observational Study
The authors aimed to document the activity worldwide from the beginning of transplantation and search for region adapted indications and associations between transplant rates and macroeconomics. [Lancet Haematol] Abstract | Press Release

Regulatory Effect of Chemokines in Bone Marrow Niche
The authors focus on the emerging role of chemokines and their receptors in normal and pathologic conditions of the bone marrow niche, and also discuss the new therapeutic methods with this background. [Cell Tissue Res] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

BioLineRx Announces Regulatory Submission for Phase IIb Trial for Novel AML Consolidation Treatment
BioLineRx Ltd. announced the filing of regulatory submissions required to commence a Phase IIb trial for BL-8040 as a novel consolidation treatment for acute myeloid leukemia (AML). [BioLineRx Ltd.] Press Release

UW to Test ‘Breakthrough’ Pediatric Leukemia Treatment
A promising method of immunotherapy to treat children with relapsed acute lymphocytic leukemia (ALL) is opening at the University of Wisconsin Carbone Cancer Center and American Family Children’s Hospital. The trial is open to relapsed/refractory pediatric ALL patients who have limited treatment options. [University of Wisconsin] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the Human Immunology Portal.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the hematopoiesis community.

Research Technologist – Hematopoietic Product Development (STEMCELL Technologies Inc.)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Position – Drug Development for Anemia (Lund University)

Postdoctoral Scientist – Hematopoietic Stem Cell Transplantation (Indiana University)

Postdoctoral Position – Pediatric Hematology and Oncology (University Medical Center of Freiburg)

Senior Process Development Engineer (Sangamo BioSciences, Inc.)

Director – Vector Production (Sangamo BioSciences, Inc.)

Postdoctoral Position – Hematopoietic Stem Cell Physiology and Pathophysiology (Kumamoto University)

Postdoctoral Position – Genetic Engineering and Transplantation of Hematopoietic Stem Cells (University of California – San Francisco)

Research Associate – Hematopoietic Stem Cells and Leukemia (City of Hope)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.